CPAP held a 65.67% share of the positive airway pressure devices market in 2025, reflecting its entrenched role as the standard therapy option for routine sleep-disordered breathing management. Its leadership is maintained through broad clinical familiarity, simpler treatment protocols, and widespread use in home-based care settings where consistent nightly therapy and operational ease matter most. In the positive airway pressure devices market, CPAP remains the leading product because it addresses a large volume of established patient demand with a straightforward treatment approach that providers and users already know well.

BiPAP is emerging as the fastest-growing product segment in the positive airway pressure devices market because it better serves patients who need differentiated inhalation and exhalation pressure support than conventional single-pressure systems can provide. Growth is being supported by expanding use in more complex breathing conditions and care situations where patient tolerance, ventilation support, and pressure flexibility are more critical. Relative to CPAP, BiPAP is gaining momentum as treatment needs become more varied and clinicians increasingly match device selection to patients requiring more tailored respiratory assistance.

Application Segment Analysis: Obstructive Sleep Apnea (Largest Segment) vs Respiratory Failures (Fastest-Growing Segment)

Obstructive Sleep Apnea accounted for the largest share of the positive airway pressure devices market in 2025, supported by the central role of positive airway pressure therapy in ongoing nighttime airway management. This application leads the market because treatment is typically long-term and device-based, creating steady demand across diagnosis, prescription, and home-use settings. Within the positive airway pressure devices market, Obstructive Sleep Apnea maintains its leading share through its direct alignment with the most established and routine use case for these devices.

Respiratory Failures represent the fastest-growing application in the positive airway pressure devices market as care providers increasingly rely on non-invasive pressure support in situations that require timely respiratory intervention without immediate escalation to more invasive measures. The segment is seeing wider adoption because these cases often demand adaptable breathing support across acute and monitored care environments, making positive airway pressure devices a practical option where clinical responsiveness is essential. Compared with more established applications, growth in Respiratory Failures is being driven by the increasing relevance of non-invasive respiratory management in patients with more intensive support needs.